COMP <GO>
IONS vs KNSA // OPERATING MARGIN
Ionis Pharmaceuticals Inc. (NASDAQ) VS. Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) • 15-METRIC TALLY: IONS 2
— KNSA 10
▲ OPERATING MARGIN LEADER: KNSA
LAST: $41.24 (-5.24%) • MKT CAP: $7.23B
operating-margins
-40.40%
LAST: $90.80 (-1.56%) • MKT CAP: $7.25B
operating-margins
11.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. KNSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | KNSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.50% | +7.50 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | 9.90% | -30.80 | KNSA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.34% | 1.78% | -6.12 | KNSA | /fcf-yield <GO> |
| Operating Margin ACTIVE | -40.40% | 11.40% | -51.80 | KNSA | /operating-margins <GO> |
| Net Profit Margin | -40.40% | 8.70% | -49.10 | KNSA | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 60.10% | -26.30 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 24.45 | -23.37 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.6 | 59.2 | -15.60 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.11 | -0.02 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 109.1x | -87.10 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.23B | $7.25B | -$15.1M | KNSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | KNSA REV | IONS GROSS % | KNSA GROSS % | IONS FCF | KNSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $677.6M | 98.3% | 88.5% | -$320.0M | $136.4M |
| FY 2024 | $705.1M | $423.2M | 98.4% | 85.6% | -$546.2M | $25.4M |
| FY 2023 | $787.6M | $270.3M | — | — | -$343.0M | $1.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
KNSA // BETA 1.11